Understand · Treat · Recover

Chemotherapy

Chemotherapy has different jobs during curative treatment and during treatment for recurrent or metastatic cancer.

Patient education only. This guide does not diagnose cancer or prescribe treatment. Your team must adapt decisions to your cancer, health, preferences and local resources.

All 25 chapters

Chapter 14 of 25

Concurrent chemoradiotherapy
  1. Radiotherapy treats the tumour and selected neck areas
  2. Systemic treatment can increase radiation effectiveness
  3. Blood tests, hydration and toxicity checks guide safe delivery

Why chemotherapy may be recommended

Chemotherapy interferes with cancer-cell growth. During concurrent chemoradiotherapy, it is given alongside radiation to help radiation work more effectively. This can improve cancer control in appropriately selected people, but also adds side effects. After surgery, concurrent chemotherapy is especially important for certain high-risk pathological findings, such as positive margins or extranodal extension, when a patient can tolerate it.

Induction chemotherapy is given before the main local treatment. It is used in selected situations, including some larynx-preservation strategies and particular nasopharyngeal cancer pathways. It is not automatically required before chemoradiotherapy for every locally advanced squamous cancer. In recurrent or metastatic disease, chemotherapy can shrink tumours, relieve symptoms and help control cancer, often as part of a combination.

Common medicines and their roles

Cisplatin is a platinum medicine with strong evidence as a radiation sensitizer in several curative head and neck settings. Carboplatin is another platinum drug used in selected combinations when the setting or a person’s health favours it; it is not a direct substitute for cisplatin in every curative plan. Paclitaxel and docetaxel are taxanes, used in some induction, recurrent-disease or cisplatin-ineligible approaches.

5-fluorouracil, often written 5-FU, is used in certain combinations and may require a continuous infusion pump. Methotrexate is used in selected recurrent-disease and metronomic approaches. The choice depends on evidence for the exact setting, kidney and liver function, previous treatment and the practical ability to deliver and monitor the regimen safely. Oral anticancer treatment still requires specialist prescribing and monitoring.

Weekly or three-weekly cisplatin?

Cisplatin may be given in smaller weekly doses or larger doses every three weeks. The comparison depends on the dose, postoperative versus definitive treatment, and the patient population. The JCOG1008 randomized trial supported a particular weekly schedule as a reasonable alternative in postoperative high-risk disease; it did not prove that any low weekly dose is equivalent in every setting.

Ask why the selected schedule fits your situation and how the team will respond if toxicity develops. A weekly schedule still carries risks to hearing, kidneys, nerves and blood counts. Receiving treatment safely and completing effective radiation are important; do not try to replace a missed dose or change the schedule yourself.

When cisplatin is unsuitable

The team assesses kidney function, hearing, nerve damage, general fitness and the ability to tolerate hydration. Significant impairment may make cisplatin unsafe; a weekly schedule does not remove these risks. Age alone is not a reliable eligibility test. Ask which specific risk changes your plan and whether it is reversible.

For selected patients receiving definitive radiation who cannot receive cisplatin, alternatives can include radiation alone or radiation with cetuximab, carboplatin/5-FU or a taxane-based approach. ASTRO conditionally recommends these systemic alternatives in appropriate HPV-positive oropharyngeal cases. They are not equally supported in every site or setting. Postoperative treatment is a separate decision: there is no universally equivalent replacement for cisplatin, and radiation alone or a clinical trial may be appropriate.

Before and during an infusion

The team checks blood counts and organ function, reviews symptoms and asks about medicines. Kidney function, hydration and electrolytes are particularly important for cisplatin. Hearing assessment may be appropriate before treatment, especially when there is existing impairment. Let the team know about ringing in the ears, hearing changes, numbness, reduced urine output or swelling.

Antinausea medicines are given before treatment, with a home plan to prevent delayed nausea. Cisplatin generally needs carefully prescribed intravenous fluids and electrolyte support. Fluid amounts are adjusted for the individual, especially with heart or kidney problems. The anticancer medicine may be given through a peripheral vein or a longer-term venous device; report burning, pain or swelling around an infusion site immediately.

Managing risks and deciding when to call

Chemotherapy can cause low blood counts, infection, nausea, vomiting, fatigue, mouth soreness, altered taste and bowel changes. Hair loss depends on the drugs; some taxane combinations cause much more than cisplatin given alone. Peripheral neuropathy is nerve damage causing tingling, numbness or weakness. Some side effects improve after treatment, while hearing or nerve injury can persist.

A temperature of 38°C or above during chemotherapy needs immediate contact with the oncology service, or emergency assessment if the service cannot be reached. Follow a lower threshold if your team has given one. Severe shivering or feeling very unwell can be urgent even without fever. Do not wait for the next blood test or use fever medicine to delay seeking help.

Call promptly for repeated vomiting, inability to drink, markedly reduced urine, severe diarrhoea, chest pain or new shortness of breath. Chest pain during 5-FU needs urgent evaluation. Keep the emergency number and treatment list with you. Supportive care and dose adjustments are part of good cancer treatment, not evidence that you have failed to cope.

References and evidence review

Evidence/editorial check: 25 October 2026. AI-assisted preparation is distinct from individual physician review. See the linked review policy for source-access limits and review status. Regulatory indications, reimbursement and availability vary by country. Trial results alone do not establish approval everywhere; your treating team should confirm the applicable current guidance.